NCT07321613Completed
Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients
Effect of Thalidomide, Carmofur and Compound Mylabris Capsules (TCC) Cocktail Combined With Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone on Survival in Patients With Unresectable Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 7 Jan 2026
Brief summary (registry, in English)
This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with conventional Transarterial Chemoembolization (TACE) for the treatment of patients with unresectable Hepatocellular Carcinoma (HCC).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 545 (actual)
- First submitted
- 23 Dec 2025
- Start date
- 1 May 2023
- Primary completion date
- 1 May 2025
- Lead sponsor
- Shanghai Zhongshan Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07321613
What you commit to
- Study type: Observational
- Participants enrolled: 545
- From 1 May 2023 to the primary completion date, 1 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- a history of previous or synchronous treatment for tumors such as radio frequency ablation (RFA) or systemic chemotherapy.
Other illness
- accompanying other life-threatening diseases.
Other
- poor liver functions (Child-Pugh class C).
Who the study is looking for
- patients who met the HCC diagnostic criteria according to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China.
- patients underwent conventional TACE.
- availability of complete medical records for data extraction and follow-up.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Hospital,Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.